Amgen hit by ivabradine failure previously reported by Servier
This article was originally published in Scrip
Amgen's stock took a small hit as investors reacted to a new publication for Servier's Phase III SIGNIFY clinical trial, which showed that ivabradine provided no heart rate-lowering benefit for patients who had stable coronary artery disease (CAD) without clinical heart failure.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.